Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of LY3848575 in Healthy Participants
NCT05727072Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2023
- Primary completion
- Feb 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY3848575 in neuropathic pain (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered Related to Study Drug. Started Feb 2023; status: completed.
02
Drugs
LY3848575
03
Conditions
neuropathic pain
Beyond the preview
Go deeper on NCT05727072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05727072.